EGFR and non-small cell lung carcinoma: Recently, the updated report of PACIFIC [7] and retrospective analysis on durvalumab consolidation for patients with stage III NSCLC [8, 9] suggested that durvalumab might have limited clinical efficacy in the small subset of patients with EGFR- or HER2-mutant NSCLC.